diagnostic procedures
Using a conventional histology only, nearly 50% of LPHL cases are misdiagnosed [6] . Differential diagnosis includes cHL, lymphocyte rich-cHL, non-Hodgkin lymphoma and reactive hyperplasia. Thus, immunohistology is required for the diagnosis of LPHL. L&H cells usually express CD20 and lack CD15 and CD30 which are the characteristic markers of cHL [7] . The differential diagnosis of NLPHL and related lymphomas is shown in Table 1 .
stage IA LPHL
The prognosis for this group of patients is extremely favourable with >95% achieving CR and excellent long-term outcome.
Thus, different treatment modalities such as watch and wait, radiotherapy only, combined modality treatment or, more recently, the anti CD20 monoclonal antibody rituximab have been evaluated in this patient population. An analysis of stage IA LPHL in children treated within a French phase II study showed no difference in overall survival between those receiving surgical adenectomy only (n = 13) and those who had additional treatment (n = 14) [8] . However, only three of nine patients remained in CR after lymphadenectomy alone whereas 15 children not in CR after lymphadenectomy had a worse prognosis using watch and wait. Overall event-free survival was 90% with combined modality and 42% with watch and wait (P < 0.04). Thus, watch and wait cannot generally be recommended in stage IA LPHL patients. A more recent analysis by the German Hodgkin Study Group (GHSG) compared different radiation fields in 131 LPHL stage IA patients. Of these, 45 patients were treated with extended field (EF) radiotherapy, 45 patients had involved field (IF) radiotherapy and 41 patients received combined modality treatment (CM). With a median follow-up of 78 months (EF), 40 months (CM) and 17 months (IF), there were no significant differences between treatment groups with 98% (EF), 100% (IF) and 95% (CM) of patients reaching CR. With a median follow-up of 43 months, there were 5% relapses and only three patients had died. Thus, IF seems to be really effective and is being regarded as standard in this group of patients though longer follow-up is required [9] .
treatment of advanced-stage LPHL
A comprehensive retrospective analysis of all LPHL patients compared with cHL patients was performed by the GHSG [10] . From a total of 394 LPHL patients, 63% were in early 
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favourable stages, 16% were in early unfavourable stages and 21% in advanced stages. Overall, 87.5% of patients with LPHL and 81.7% of 7904 cHL patients achieved CR (P = 0.0034). Also for the subgroup of early favourable patients, there were significant differences in response (91.6% versus 85.9%; P = 0.0145). General risk factors for treatment failure as measured by freedom from treatment failure included advanced stage, low haemoglobin and lymphopenia (Table 2) .
new approaches
Given that both the malignant L&H cells and the reactive background are strongly positive for the B-cell marker CD20, the chimeric anti-CD20 monoclonal antibody rituximab was evaluated in phase II studies in LPHL patients, demonstrating impressive activity even in those with multiple relapses [11, 12] . A recent update of the GHSG trial confirmed these earlier reports with 92% of patients alive and 50% progression free after a median observation time of 63 months [13] . On the basis of these provocative data, the GHSG has conducted a phase II study with standard-dose rituximab in stage IA LPHL patients. In addition, there are reports that rituximab might also be effective in cHL. Here, a combination of rituximab and ABVD resulted in event-free survival of 85% and overall survival of 88% [14] . Thus, our group is currently evaluating the additional use of rituximab in PET-positive advanced-stage cHL patients receiving eight cycles of BEACOPP escalated .
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